Clinically significant anemia in HIV-infected pregnant women in India is not a major barrier to zidovudine use for prevention of maternal-to-child transmission

Post Date: 
2007-06-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Journal of Acquired Immune Deficiency Syndromes
Summary: 

Objectives: To determine the prevalence of anemia (serum hemoglobin <10 g/dL) and assess zidovudine use and toxicity in HIV-positive pregnant women in India.


 


Methods: From 2002 through 2006, 24,105 pregnant women in Pune were screened for HIV and anemia. As part of an infant prevention of mother-to-child transmission (PMTCT) trial, enrolled HIV-positive women (n = 467) were assessed for anemia and associated outcomes, comparing women receiving zidovudine for >or=2 weeks versus no zidovudine.

Citation: 
Sinha G, Choi GJ, Nayak U, Gupta A, Nair S, Gupte N, Bulakh PM, Sastry J, Deshmukh SD, Khandekar MM, Kulkarni V, Bhosale RA, Bharucha KE, Phadke MA, Kshirsager AS, Bollinger RC. Clinically significant anemia in HIV-infected pregnant women in India is not a major barrier to zidovudine use for prevention of maternal-to-child transmission. J Acquir Immune Defic Syndr. 2007 Jun 1; 45:210-217.
Collaborators: 


  • Byramjee Jejeebhoy Medical College, Pune, India

  • ED SEARCH, Pune, India

  • Kolhapur Medical College, Kolhapur, India

  • Institute of Health Management-Pachod, Pune, India

  • Maharashtra University of Health Sciences, Nashik, India

  • Modern College, Pune, India